Composition, form of production and packaging
? Tablets for resorption of flat-cylindrical shape, with a risk and chamfer, from white to almost white. On the flat side, the inscription MATERIA MEDICA is marked with a risk, on the other flat side is inscribed CARDOSTEN.
antibodies to the C-terminal fragment of the AT1 receptor of angiotensin II 0.003 g *
* are introduced in the form of a water-alcohol mixture of the active form of the active ingredient
Excipients: lactose, microcrystalline cellulose, magnesium stearate.
20 pcs. - packings of cellular contour (1) - packs cardboard.
20 pcs. - packings cellular planimetric (2) - packs cardboard.
20 pcs. - packings cellular planimetric (5) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2013.
The drug modulates the functional activity of the AT 1 subtype of angiotensin II receptors in various tissues.
In conditions of chronic heart failure, the drug reduces arterial vasoconstriction, peripheral vascular resistance, pre - and postnagruzku on the heart. Modifies the effect of angiotensin II on the structure and function of resistive vessels, remodeling processes in the cardiovascular system; positively affects the morphofunctional parameters of the heart, including helps reduce myocardial hypertrophy, reduce the volume of dilated heart chambers, normalize myocardial oxygenation. By increasing the stroke volume increases the minute volume of blood flow, without changing the heart rate.
The drug increases exercise tolerance and improves the functional class of CHF. Taking a drug lasting two or more months is accompanied by an improvement in hemodynamic parameters; leads to the normalization of the daily rhythm of blood pressure (does not affect blood pressure at its normal level, reduces blood pressure at initially elevated values, reduces its fluctuations during the day).
Does not adversely affect the water-salt balance.
In the complex therapy of chronic heart failure:
- to reduce shortness of breath, weakness, severity of peripheral edema;
- to increase tolerance to physical activity.
Inside. The drug is taken for a long time. The first 2-3 months of treatment with Cardosten is carried out without canceling the previously prescribed complex therapy for chronic heart failure, the amount of which can be changed in the future by the attending physician.
At one time - 1 tablet (keep in your mouth until completely dissolved - not during meals). If necessary, it is possible to use 2 tablets at the reception.
The first 2-3 months the drug is taken 3 times a day. With the improvement of the state, it is sufficient to take two doses of the drug on the day before the night's sleep and in the morning.
Possible reactions of increased individual sensitivity to the components of the drug.
- increased individual sensitivity to the components of the drug;
- age to 18 years.
PREGNANCY AND LACTATION
The safety of the use of Cardosten in pregnant women and during lactation has not been studied. If necessary, taking the drug should take into account the risk / benefit ratio.
APPLICATION FOR CHILDREN
Contraindicated in children under 18 years of age
The composition of the drug includes lactose, and therefore it is not recommended for patients with congenital galactosemia, glucose malabsorption syndrome or galactose, or with congenital lactase deficiency.
There have been no cases of overdose to date.
In case of an accidental overdose, dyspepsia is possible due to the excipients included in the formulation.
Cases of incompatibility with other drugs have not been identified to date.
TERMS OF RELEASE FROM PHARMACY
TERMS AND CONDITIONS OF STORAGE
In a dry, the dark place at a temperature of no higher than 25 В° C. Keep out of the reach of children. Shelf life - 3 years.